What NICE's Tirzepatide Guidance Means for People Living with Obesity

The biggest myth: NICE approval means anyone with obesity can get it on the NHS now

The most common misconception circulating online is that NICE recommending tirzepatide means it is now freely available through a GP for any adult who is overweight. That is not what NICE TA1026 says. The recommendation applies to adults with a BMI of 35 or above who also live with at least one qualifying comorbidity, conditions that include high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. BMI alone is not a sufficient reason under the NICE criteria.

NHS England is also phasing the rollout in stages. From June 2025 the first cohort became eligible: adults with a BMI of 40 or above alongside four or more of those five conditions. A second cohort opened in June 2026, extending access to adults with a BMI of 35–39.9 and four or more conditions. A further expansion to three qualifying conditions is planned from around March 2027. Each phase has its own BMI floor and comorbidity count, and even meeting the criteria does not guarantee immediate access, since GP practices can opt into prescribing under the new contract on a voluntary basis. Availability therefore varies by practice and area.

For people who fall outside these cohorts or prefer not to wait, a private tirzepatide prescription through a regulated online pharmacy is the alternative route, subject to clinical suitability. The licensed eligibility for private prescribing is broader (adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition) though a prescriber still decides whether treatment is appropriate for each individual.

What the clinical trial evidence behind TA1026 actually showed

NICE's recommendation rests substantially on the SURMOUNT programme of trials, particularly SURMOUNT-1, which enrolled 2,539 adults with obesity and reported around 20–21% average body-weight reduction at the 15 mg dose over 72 weeks. Those are meaningful figures, and the TA1026 recommendations chapter reflects the committee's view that the evidence is robust enough to justify NHS use in the defined population.

Head-to-head evidence has since strengthened that picture further. SURMOUNT-5, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4 mg in adults with obesity but without diabetes over 72 weeks. Tirzepatide produced greater average weight reduction in that trial. It matters for readers comparing Mounjaro with Wegovy, because the NICE appraisal pre-dates SURMOUNT-5 and relies on indirect comparisons; the head-to-head data arrived later.

One practical detail the trial evidence informs: tirzepatide starts at 2.5 mg as a tolerability dose, with the prescriber titrating upward typically in four-week steps. The therapeutic effect builds with dose. Seeing modest early results does not mean the medicine is not working; it reflects where you are on the schedule. For a fuller picture of how the evidence compares across treatments, the phase 2 obesity data page adds useful context on the earlier-stage trial findings that shaped the SURMOUNT programme.

Who NICE's thresholds include that the headlines often miss

The BMI figures in TA1026 are not universal. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the NICE thresholds are set 2.5 kg/m² lower, recognising that cardiometabolic risk accumulates at lower BMI in these groups. That means the main NICE threshold of BMI 35 becomes effectively 32.5 for those backgrounds, a clinically significant adjustment that is easy to overlook in summarised versions of the guidance.

There is also the stopping rule, which the guidance specifies clearly. If a person has lost less than 5% of their starting body weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. This is not a failure clause, it is a built-in clinical checkpoint that ensures the medicine is doing what it is supposed to do before longer-term commitment. Our NICE tirzepatide overview covers the committee's reasoning on this point in more detail.

On cost, the NICE appraisal considers tirzepatide cost-effective at the agreed NHS price. Private treatment costs are a separate matter: Eli Lilly raised the UK list price from 1 September 2025, with the highest-dose pen moving from around £122 to around £330 per four-week pen, and typical private prices since then range roughly £149–£375 per month depending on dose and provider. For a clearer picture of what private prescribing costs and what those prices include, the Mounjaro pricing page sets this out plainly, including what a single transparent price from a regulated service covers and what it does not.

What to do if you think you might be eligible

If you meet the NICE criteria, your starting point is a conversation with your GP, though given that practice participation is voluntary, it is worth asking directly whether your surgery is prescribing tirzepatide under the new contract. Waiting lists for NHS specialist weight management services, through which Wegovy has been available, are commonly long; some people find the NHS route takes considerably longer than they expected, especially if they sit on the boundary of a cohort threshold.

Private treatment is not the right fit for everyone. The clinical assessment is real, the eligibility criteria apply, and a prescriber is assessing your whole health picture rather than simply checking a number. If you are unsure where you stand, the NICE tirzepatide weight-loss eligibility page walks through the private-route criteria in plain terms.

Ordering is straightforward once you have been assessed: order by midday Monday to Friday and, once a prescriber has reviewed and approved your consultation, treatment is dispatched the same day and arrives the following working day. If a holiday or a payday falls awkwardly, it is worth knowing that the same-day dispatch window simply requires the 12pm Monday-to-Friday cut-off, nothing more complicated than that. You can learn more about how our prescribers work on the clinical team page, and the FAQs cover the most common questions about what the process involves. When you are ready to take the next step, you can speak to our prescribers through a free consultation, no obligation, no commitment until you decide.